rat monoclonal anti epha2 pe (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
93
Structured Review
R&D Systems
rat monoclonal anti epha2 pe
Rat Monoclonal Anti Epha2 Pe, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat monoclonal anti epha2 pe/product/R&D Systems
Average 93 stars, based on 13 article reviews
Rat Monoclonal Anti Epha2 Pe, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat monoclonal anti epha2 pe/product/R&D Systems
Average 93 stars, based on 13 article reviews
rat monoclonal anti epha2 pe - by Bioz Stars,
2026-02
93/100 stars
Images
1) Product Images from "Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment"
Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment
Journal: bioRxiv
doi: 10.1101/2024.09.25.615079
Figure Legend Snippet: A) Analysis of log 2 transformed FPKM gene expression values extracted from bulk RNA seq published previously (Smith R. et al. Scientific Reports 2020 ) shows high EphA2 expression in castration resistant, commercially available human PCa cell lines. B) Immunoblot characterization of select human PCa cell lines show increased EphA2 expression and S897 phosphorylation in mCRPC derived cell lines. C) EphA2 expression in representative human prostate cancer cell lines. D) Lysate of human prostate cancer tissues reveal increased expression of EphA2 in bone metastasis samples. Lysates were prepared from micro-dissected human prostate cancer tissues under the Rapid Autopsy Program at the Univ. Mich. PCa SPORE.
Techniques Used: Transformation Assay, Expressing, RNA Sequencing Assay, Western Blot, Derivative Assay
Figure Legend Snippet: A) Diagram depicting the serial propagation of TRAMP-C1 cells in syngeneic mice to select for cells with increased tumorigenic capacity. B) The in vivo selection of cells resulted in accelerated tumor growth and reduced latency. C) Immunoblot analyses of the in vivo selected (IV1) and the parental TRAMP-C1 cells using the indicated antibodies. D,E,F,G,H,I,J) Quantification of relative band intensity (n = 4). All bands normalized to tubulin, except for pY588 and pS897 which are normalized to total EphA2 expression. K) Immunoblot of TRAMP-C1 parental and IV1 cells after stimulation with Ephrin-A1-Fc ligand for the indicated times. L,M) MPC3 and MycCaP cells were propagated in syngeneic C57Bl/6 and FVB mice, respectively. Lysates of the parental and the in vivo selected cells (IV1) were subject to immunoblot using the indicated antibodies.
Techniques Used: In Vivo, Selection, Western Blot, Expressing
Figure Legend Snippet: A) Immunohistochemical (IHC) analyses of tissue microarray (TMA) prepared from primary, lymph node metastatic (LN), and bone metastatic human PCa tissues from the Rapid Autopsy Program of the Pacific Northwest PCa SPORE spotted. B and C) The relative IHC staining strengths of EphA2 and pS897-EphA2 on TMA was scored using 0-3 scale (0, absent; 1, weak; 2, moderate; 3, strong) . Data consists of 27 bone metastatic samples, and 18 soft tissue samples including 10 lymph node, 5 liver, and 3 lung metastatic samples. Comparisons were made using an unpaired t-test (B, p = 0.0003 C, p < 0.0001) D) mRNA expression analysis of human PCa metastatic biopsies revealed that bone metastases have the highest EphA2 expression compared to other sites of disease dissemination. Data from 208 samples from the SU2C/PCF Dream Team. mRNA Expression z-scores relative to all samples (log FPKM Capture) accessed via cBioportal. E) Kaplan-Meier curve of patients with bone metastases according to the levels of EphA2 expression.
Techniques Used: Immunohistochemical staining, Microarray, Immunohistochemistry, Expressing
Figure Legend Snippet: A) Immunoblot analysis of PC3 cells transduced with lentivirus to express WT-EphA2 or S897A-EphA2. Empty vector-transduced cells were used as control. Cells were starved for 24 hours in serum-free medium and stimulated with either FBS alone or FBS togethr with ephrin-A1-Fc. B) PC3 cells overexpressing WT-EphA2 or S897A-EphA2 mutant were xenografted subcutaneously into nude mice (n = 10 per group). Vector alone cells were used as control. Comparison between WT-EphA2 and S897A-EphA2 made with an unpaired t-test at day 46 post-injection (p = 0.0402).
Techniques Used: Western Blot, Transduction, Plasmid Preparation, Control, Mutagenesis, Comparison, Injection
Figure Legend Snippet: A) Analysis of log 2 transformed FPKM gene expression values extracted from bulk RNA seq published previously (Smith R. et al. Scientific Reports 2020 ) showing low Efna1-5 gene expression in commercially available castration resistant and androgen sensitive human PCa cell lines. B) Immunoblot characterization of select PCa cell lines reveals simultaneous high EphA2 expression and low EphrinA1 expression in metastatic castration resistant cells compared with androgen sensitive cells. C ) Quantitative analysis of data in (B). D) Kaplan-Meier survival curve from the MSK dataset ( Cancer Cell 2010 ). Samples were aggregated into the top 25 percent EFNA1 expressing ( EFNA1 High), and lower 75 percent EFNA1 expressing ( EFNA1 Low). Data were accessed via cBioportal.
Techniques Used: Transformation Assay, Expressing, RNA Sequencing Assay, Western Blot
Figure Legend Snippet: A) Lysates of PC-3 cells transduced by lentiviral vector expressing EFNA1 (EA1) or empty control vector were subject to immunoblot with the indicated antibodies. B,C) Quantification of pY588 marking canonical signaling and pS897 marking noncanonical signaling by EphA2, relative to total EphA2 expression. D) Vec. and EA1-expressing PC-3 cells were stimulated with recombinant exogenous EA1-Fc ligand in vitro for the indicated times, and lysates were subject to immunoblot with the indicated antibodies. E) PY99, a monoclonal antibody that recognizes most pY motifs, was used to probe overall pY profiles using lysates from Vec. and EA1-expressing PC-3 cells stimulated with EA1-Fc. N-cadherin and pY416-Src were also probed. F) PC-3 cells expressing EA1 exhibit reduced cell growth in an in vitro cell proliferation assay. G) Vec. control and EA1-expressing cells were implanted subcutaneously into nude mice. Paired t-test to be used to monitor (p = 0.0319). G) Bioluminescence imaging of mice four and six weeks after intratibial injection of PC3-vec. or PC-3-EA1 expressing cells tagged with luciferase. H) X-ray imaging of mice 6 weeks post intratibial injection of PC3-Vec and PC3-EA1 cells.
Techniques Used: Plasmid Preparation, Expressing, Control, Western Blot, Recombinant, In Vitro, Proliferation Assay, Imaging, Injection, Luciferase
![In vitro specificity of [ 68 Ga]AJ201 for EphA2 in human pancreatic cancer cells. A) Quantification of EphA2-mRNA using RT-PCR. B) Flow cytometry analysis of EphA2 receptor expression on cell surface. C) A representative plot of EphA2 receptor density in PDAC cells measured by quantibrite assay. D) [ 68 Ga]AJ201 binding (percent incubated activity, %IA) to different cells. Cells were incubated with 1 µCi [ 68 Ga]AJ201 at 4 °C for 1 h. [ 68 Ga]AJ201 uptake is EphA2 expression dependent, and co-incubation with 2 μM of non-radioactive AJ201 (0.2 nmol, blocking dose) significantly reduced radiotracer uptake confirming EphA2 specificity. E) In vitro uptake of [ 68 Ga]AJ201 over 60 min in Panc1 cells at 4 ˚C and 37 ˚C. F) Correlation of [ 68 Ga]AJ201 uptake with surface EphA2 receptor density. Data in panels A , D , E and F are presented as mean ± SD (n = 3-4). Significance was calculated using multiple unpaired t test in D ; ns, P ≥ 0.05; *, P ≤ 0.05; ***, P ≤ 0.001; ****, P ≤ 0.0001. Simple linear regression and Pearson coefficient were used in F . All in vitro experiments were performed three times and representatives are shown.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_4392/pmc11984392/pmc11984392__thnov15p4229g003.jpg)
![In vivo specificity of [ 68 Ga]AJ201 for EphA2 in NSG mice with PDAC tumor xenografts. A) Whole-body PET/CT images of different human PDAC xenografts at 60 min after the injection of radiotracer. Mice were injected with ~ 7.4 MBq (~200 µCi) [ 68 Ga]AJ201; K, kidney. Panc1 mouse image is reproduced from figure E. B) [ 68 Ga]AJ201 uptake quantification (%ID/g) in different PDAC tumors by ex vivo biodistribution at 60 min after injection. Left: %ID/g of different tumor xenografts, tumor-to-blood (middle) and tumor-to-muscle (right) ratios in each individual mice harboring respective xenografts. C) IHC staining for EphA2 expression in PDAC xenografts (digitally scanned at 40x).; data in figure B is shown as box and whisker plots (median ± IQR) showing all data points (n = 4-5).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_4392/pmc11984392/pmc11984392__thnov15p4229g005.jpg)
![In vivo distribution of [ 68 Ga]AJ201 in Panc1-orthotopic tumor model. A) Coronal sections of the fused PET/MR images showing [ 68 Ga]AJ201 distribution. Primary tumor is indicated by red circle; K = Kidney, B = Bladder. B) Quantification of accumulated activity in tumor, muscle and pancreas of images shown in panel A (n = 4-5) C) tumor-to-muscle (T/M) and tumor-to-pancreas (T/P) ratios from the images shown in panel A (n = 4) D) EphA2 IHC of orthotopic Panc1 tumor and normal pancreas to validate the EphA2 expression. Panc1 orthotopic tumor model was generated by surgically implanting a 3-5 mm³ section of Panc1 tumor xenograft directly onto the pancreas. The implanted tumors were allowed to grow for 10 days, after which they were ready for imaging. At this stage, MRI measurements indicated that tumor sizes ranged from 10-50 mm 3 . data in figure B and C is shown as box and whisker plots (median ± IQR) showing all data points (n = 3-5).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_4392/pmc11984392/pmc11984392__thnov15p4229g006.jpg)